This is the first study to directly compare ibrutinib, acalabrutinib and zanubrutinib treatment on PD-1, TIM3 and LAG3 expression on proliferating T cells from patients with CLL, and highlights the differential impacts of different BTKi on T cell function. The gene discussed is HAVCR2; the disease is B-cell chronic lymphocytic leukemia.